Anxiety disorders are common, impair functioning and quality of life, and frequently co-occur with depression and substance use. Causes are multifactorial, including genetic vulnerability, alterations in stress-response circuitry, chronic psychosocial stressors, and learned avoidance behaviors. Cultural expectations about emotional expression, local economic conditions, and territorial factors such as conflict or displacement shape both risk and presentation, so prevalence and treatment access vary between communities. Untreated anxiety can lead to lost work productivity, strained relationships, and increased use of health services; the World Health Organization identifies anxiety disorders among leading contributors to years lived with disability worldwide.
Evidence-based therapies
Psychological treatments are the foundation of effective care. Cognitive behavioral therapy emphasizes restructuring unhelpful thought patterns and graded exposure to feared situations, producing durable reductions in symptoms across generalized anxiety disorder, panic disorder, social anxiety disorder, and specific phobias. Research by David H. Barlow at Boston University has long documented the efficacy of structured cognitive behavioral protocols for panic and other anxiety disorders. Meta-analyses by Stefan G. Hofmann at Boston University support CBT as a consistently effective modality across adult anxiety disorders. For many patients, exposure-based elements that directly address avoidance are the active ingredient that reduces long-term relapse risk. Where face-to-face therapy is limited by geography or stigma, internet-delivered CBT has been validated as an effective alternative by Gerhard Andersson at Linköping University, with particular utility for mild to moderate presentations and for expanding access in underserved regions.
Medication and combined approaches
Pharmacotherapy complements psychotherapy for many adults. Selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors are commonly prescribed and recommended in clinical guidelines from the National Institute for Health and Care Excellence and the American Psychiatric Association for multiple anxiety disorders because of consistent evidence for symptom reduction and functional improvement. Short-term use of benzodiazepines can relieve acute severe anxiety but carries risks of dependence and cognitive side effects, and guideline authors advise limiting duration. Combining medication with CBT can accelerate symptom relief and may be preferable for severe or disabling illness, though psychotherapy alone produces enduring skill-based benefits that protect against relapse once medication stops.
Implementation, follow-up, and social context
Effective treatment requires accurate diagnosis, attention to comorbidity, and shared decision-making that respects cultural beliefs about mental health. Workforce shortages, stigma, and uneven health insurance coverage create territorial disparities in who receives evidence-based care; community-informed adaptations improve engagement among diverse populations. Monitoring for side effects, functional outcomes, and relapse is essential; stepped-care models allow clinicians to intensify or change interventions when response is partial. Public health investments in training primary care clinicians to deliver brief CBT interventions, expanding telehealth, and addressing social determinants of stress can reduce the population burden of anxiety and improve outcomes for adults across different cultural and environmental contexts.